ET-743: A novel agent with activity in soft-tissue sarcomas

Current Opinion in Oncology

Volumn 18, Issue 4, 2006, Pages 347-353

  Fayette, Jérôme ^a   Coquard, Isabelle Ray ^b   Alberti, Laurent ^b   Boyle, Helen ^b   Méeus, Pierre ^b   Decouvelaere, Anne Valérie ^b   Thiesse, Philippe ^b   Sunyach, Marie Pierre ^b   Ranchère, Dominique ^b   Blay, Jean Yves ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

DNA binding; ET 743; Hepatic toxicity; Nucleotide excision repair; Sarcoma

Indexed keywords

3 INDOLEMETHANOL; ALKYLATING AGENT; BETA NAPHTHOFLAVONE; CISPLATIN; CYTOCHROME P450 INHIBITOR; DEXAMETHASONE; DOXORUBICIN; IFOSFAMIDE; TRABECTEDIN; TRANSCRIPTION FACTOR; VANCOMYCIN;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; BILE DUCT DISEASE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLINICAL TRIAL; CYTOTOXICITY; DNA BINDING; DNA DAMAGE; DOSE RESPONSE; DRUG STRUCTURE; EXCISION REPAIR; FEBRILE NEUTROPENIA; FOLLOW UP; GENE EXPRESSION; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; SURVIVAL RATE; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TOXICITY; TRANSAMINITIS; TREATMENT FAILURE;

EID: 33748033029     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000228740.70379.3f     Document Type: Review

References (62)

1. Clark MA, Fisher C, Judson I, et al. Soft-tissue sarcomas in adults. N Engl J Med 2005; 353:701-711. An important review on the biology and current standard treatment options in soft-tissue sarcomas.
2. Blay JY, van Glabbeke M, Verweij J, et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003; 39:64-69.
3. Nielsen OS, Blay JY, Verweij J, et al. Metastastic soft tissue sarcoma in adults: prognosis and treatment options. Am J Cancer 2003; 2:1-7.
4. Pommier Y, Kohlhagen G, Bailly C, et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996; 35:13303-13309.
5. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999; 42:2493-2497.
6. David-Cordonnier MH, Gajate C, Olmea O, et al. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol 2005; 12:1201-1210. An interesting review on the modes of interaction of ET-743 with DNA and non-DNA targets.
7. Bonfanti M, La Valle E, Fernandez Sousa Faro JM, et al. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 1999; 14:179-186.
8. Minuzzo M, Marchini S, Broggini M, et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 2000; 97:6780-6784.
9. Minuzzo M, Ceribelli M, Pitarque-Marti M, et al. Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. Mol Pharmacol 2005; 68:1496-1503.
10. Jin S, Gorfajn B, Faircloth G, et al. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 2000; 97:6775-6779.
11. Kanzaki A, Takebayashi Y, Ren XQ, et al. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. Mol Cancer Ther 2002; 1:1327-1334.
12. Manara MC, Perdichizzi S, Serra M, et al. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line. TC-71 Int J Oncol 2005; 27:1605-1616.
13. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002; 359:1301-1307.
14. Allander SV, Illei PB, Chen Y, et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002; 161:1587-1595.
15. Haura EB, Turkson J, Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005; 2:315-324.
16. Friedman D, Hu Z, Kolb EA, et al. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002; 62:3377-3381.
17. Takebayashi Y, Pourquier P, Yoshida A, et al. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc Natl Acad Sci USA 1999; 96:7196-7201.
18. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001; 92:583-588.
19. Takebayashi Y, Goldwasser F, Urasaki Y, et al. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res 2001; 7:185-191.
20. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001; 37:97-105.
21. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001; 7:961-966.
22. Zewail-Foote M, Li VS, Kohn H, et al. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem Biol 2001; 8:1033-1049.
23. Soares DG, Poletto NP, Bonatto D, et al. Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. Biochem Pharmacol 2005; 70:59-69. This paper shows the limited cytotoxic activity of ET-743 in the absence of NER enzymes in eukaryotic cells.
24. Maki R, Taron M, Van Oosterom A, et al. A deficient homologous recombination DNA repair (HRR) appears to cluster sarcoma patients sensitive to Yondelis (ET-743, trabectedin). 11th Annual Connective Tissue Oncology Society Meeting 2005; Boca Raton; 19-21 November 2005. Connective Tissue Oncology Society. Abstract 446.
25. Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001; 7:2908-2911.
26. Carnero A, Moneo V, Serrelde BG, et al. Mutated P correlates with extreme sensitivity to Yondelis in low passaged cell lines explanted from chemonaive sarcoma patients. 11th Annual Connective Tissue Oncology Society Meeting 2005; Boca Raton; 19-21 November 2005; Connective Tissue Oncology Society. Abstract 445.
27. Biroccio A, Gabellini C, Amodei S, et al. Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells. Mol Pharmacol 2003; 63:632-638.
28. Marchini S, Marrazzo E, Bonomi R, et al. Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743. Eur J Cancer 2005; 41:323-333.
29. Martinez N, Sanchez-Beato M, Carnero A, et al. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 2005; 4:814-823.
30. Shao L, Kasanov J, Hornicek FJ, et al. Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations. Biochem Pharmacol 2003; 66:2381-2395.
31. van Kesteren C, de Vooght MM, Lopez-Lazaro L, et al. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. Anticancer Drugs 2003; 14:487-502.
32. Beumer JH, Rademaker-Lakhai JM, Rosing H, et al. Trabectedin (Yondelis(TM), formerly ET-743), a mass balance study in patients with advanced cancer. Invest New Drugs 2005; 23:429-436.
33. Reid JM, Kuffel MJ, Ruben SL, et al. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin Cancer Res 2002; 8:2952-2962.
34. Brandon EF, Meijerman I, Klijn JS, et al. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anticancer Drugs 2005; 16:935-943.
35. Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 2005; 6:780-789.
36. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22:1480-1490.
37. Blay JY, Le Cesne A, Verweij J, et al. A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2004; 40:1327-1331.
38. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23:576-584. The final report of the largest Phase II trial showing activity of ET-743 in soft-tissue sarcomas progressing after doxorubicin and ifosfamide treatment.
39. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005; 23:5484-5492. The report of the Phase II trial of ET-743 in chemo-naive patients with advanced soft-tissue sarcomas and showing high levels of activity.
40. Schöffski P, Huygh G, Clement P, et al. Tumor control and objective responses: single-center experience with Ecteinascidin-743 (ET-743, Yondelis), an active compound for the treatment of patients with advanced soft tissue and bone sarcomas. Proceedings of the American Society of Clinical Oncology 2005; Orlando; 13-17 May 2005. American Society of Clinical Oncology. Abstract 9027.
41. Donald S, Verschoyle RD, Edwards R, et al. Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat. Cancer Res 2002; 62:4256-4262.
42. Beumer JH, Schellens JH, Beijnen JH. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacol Res 2005; 51:391-398. A comprehensive review on mechanisms of liver toxicity of ET-743.
43. Puchalski TA, Ryan DP, Garcia-Carbonero R, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002; 50:309-319.
44. Donald S, Verschoyle RD, Greaves P, et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res 2003; 63:5902-5908.
45. Donald S, Verschoyle RD, Greaves P, et al. Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro. Cancer Chemother Pharmacol 2004; 3:305-312.
46. Donald S, Verschoyle RD, Greaves P, et al. Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma. Int J Cancer 2004; 111:961-967.
47. Albella B, Faircloth G, Lopez-Lazaro L, et al. In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results. Eur J Cancer 2002; 38:1395-1404.
48. Gomez SG, Bueren JA, Faircloth GT, et al. In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells. Exp Hematol 2003; 31:1104-1111.
49. Allavena P, Signorelli M, Chieppa M, et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005; 65:2964-2971. A potential novel important biological activity of ET-743 on cells from monocyte macrophage lineages.
50. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22:890-899.
51. Van Glabbeke M, Verweij J, Judson I, et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38:543-549.
52. Samuels BL, Rushing D, Chawla SP, et al. Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy. Proceedings of the American Society of Clinical Oncology 2004; New Orleans; 5-8 June 2004. American Society of Clinical Oncology. Abstract 9000.
53. Laverdiere C, Kolb EA, Supko JG, et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003; 98:832-840.
54. Scotlandi K, Perdichizzi S, Manara MC, et al. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res 2002; 8:3893-3903.
55. D'Incalci M, Colombo T, Ubezio P, et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003; 39:1920-1926.
56. Grasselli G, Malossi A, Colombo N, et al. Phase I and pharmacokinetic (PK) study of ecteinascidin-743 (ET, Trabectedin) and cisplatin (P) combination in pre-treated patients (pts) with selected advanced solid tumors. Proceedings of the American Society of Clinical Oncology 2003; Chicago; 31 May-3 June 2003. American Society of Clinical Oncology. Abstract 542.
57. Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003; 52:131-138.
58. Takahashi N, Li WW, Banerjee D, et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001; 7:3251-3257.
59. Cohen RB, Schilder RJ, Cheng J, et al. Final results of a combination study between trabectedin and pegylated liposomal doxorubicin in patients with advanced malignancies. Proceedings of the American Society of Clinical Oncology 2005; Orlando; 13-17 May 2005. American Society of Clinical Oncology. Abstract 3074.
60. Riccardi A, Meco D, Ubezio P, et al. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anticancer Drugs 2005; 16:811-815.
61. Morioka H, Weissbach L, Vogel T, et al. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res 2003; 9:1211-1217.
62. Simoens C, Korst AE, De Pooter CM, et al. In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects. Br J Cancer 2003; 89:2305-2311.